Morgan Lewis partners Christopher Betti, associate Jacqueline Berman, and associate Jennifer Dienes authored an article for Biosimilar Development about US Food and Drug Administration guidance on the nonproprietary naming of biologics. The article discusses the four key changes to the FDA’s approach and the implications of these updates.